Compositions and methods for the treatment of drug-induced hand-foot syndrome
Patent Number: US9220713
Executive Summary:
General Description:
Hand-foot syndrome (HFS), also known as palmar-plantar erythrodysethesia (PPE), occurs in a 25%-50% of patients treated with several commonly used anti-cancer drugs including capecitabine and sunitinib. These drugs are known to improve survival in many cancers, including cancers of the colon, stomach, liver, breast, kidney, and GI stromal tumors (GIST). Worldwide, over 400,000 patients per year are treated with one of these agents. HFS involves skin changes, such as swelling, peeling, and blistering of the palms and soles, which is often painful and debilitating. As a result, HFS-related symptoms can frequently lead to dose reduction and/or discontinuation of otherwise effective anti-cancer treatment. There is no treatment for HFS other than dose reduction or stopping treatment. This invention could quickly lead to treatments to prevent and/or treat HFS and help patients avoid debilitating side effects while continuing otherwise effective treatments for their cancer.
Strengths:
Weaknesses:
Patent Status:
Inventor Bio: Herbert Hurwitz
https://medicine.duke.edu/faculty/herbert-ira-hurwitz-md
Executive Summary:
- Invention Type: Therapeutic
- Patent Status: Issued (Grant date: 2015-12-29)
- Patent Link: https://patents.google.com/patent/US9220713/
- Research Institute: Duke University
- Disease Focus: Hand-foot syndrome
- Basis of Invention: Hand-foot syndrome (HFS), also known as palmar-plantar erythrodysethesia (PPE), occurs in a 25%-50% of patients
- How it works: Application of topical sildenafil (a phosphodiesterase inhibitor) to control HFS
- Lead Challenge Inventor: Other phosphodiesterase inhibitors
- Inventors: Hurwitz; Herbert (Hillsborough, NC)
- Development Stage: 8 patients (treated with Topical sildenafil, a phosphodiesterase type 5 inhibitor)
- Novelty: A novel method of controlling one of the side effects of cancer therapy (hand-foot syndrome) that could help patients continue their therapy with appropriate doses and with no discontinuation
- Clinical Applications: Controlling one of the side effects of cancer therapy (hand-foot syndrome)
General Description:
Hand-foot syndrome (HFS), also known as palmar-plantar erythrodysethesia (PPE), occurs in a 25%-50% of patients treated with several commonly used anti-cancer drugs including capecitabine and sunitinib. These drugs are known to improve survival in many cancers, including cancers of the colon, stomach, liver, breast, kidney, and GI stromal tumors (GIST). Worldwide, over 400,000 patients per year are treated with one of these agents. HFS involves skin changes, such as swelling, peeling, and blistering of the palms and soles, which is often painful and debilitating. As a result, HFS-related symptoms can frequently lead to dose reduction and/or discontinuation of otherwise effective anti-cancer treatment. There is no treatment for HFS other than dose reduction or stopping treatment. This invention could quickly lead to treatments to prevent and/or treat HFS and help patients avoid debilitating side effects while continuing otherwise effective treatments for their cancer.
Strengths:
- No successful therapy is yet out there
Weaknesses:
- Has been tested on very few patients
Patent Status:
- Priority date: 2009-10-16
- Filing date: 2010-10-15
- Publication date: 2015-12-29
- Grant date: 2015-12-29
Inventor Bio: Herbert Hurwitz
https://medicine.duke.edu/faculty/herbert-ira-hurwitz-md
